The intranasal Alzheimer’s vaccine will be tested in humans for the first time

Brigham and Women’s Hospital in Boston starts the first human study of an intranasal vaccine against Alzheimer’s disease. Its purpose is to prevent or slow the progression of the disease.

The study is small – 16 people aged 60 to 85 with symptoms of Alzheimer’s disease will receive two doses of the vaccine one week apart. The vaccine spray a medicine called Protollin directly into the nasal passages to activate immune cells.

Jeffrey Cummings, a professor at the University of Nevada in Las Vegas, emphasizes that the concept is not entirely new, but is especially promising now that scientists have a better understanding of how to treat the disease.

“The idea of ​​activating immune cells is becoming increasingly important to the idea of ​​treating Alzheimer’s disease,” Cummings told Business Insider. He added that Nasal spray may be better at delivering Protollin to immune cells than an infusion or inhaler.

About Peter Wilson

In love with technology, with an eye towards smartphones, he does not disdain any activity linked to the Nerd world. TV series, movies, manga, anime, and comics (Marvel addicted) are the order of the day.

Check Also

Unexpected protection against autoimmune diseases

A team of researchers at Brigham and Women’s Hospital conducted a large study called Vitamin …

Leave a Reply

Your email address will not be published.